Review Article

Metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline

Maggie Wang¹, Jennifer E Norman¹, Vivek J Srinivasan³, John C Rutledge²

¹School of Medicine, University of California Davis, USA; ²Department of Internal Medicine, Division of Cardiology, University of California Davis, USA; ³Department of Biomedical Engineering, University of California Davis, USA

Received October 9, 2016; Accepted October 27, 2016; Epub November 30, 2016; Published December 15, 2016

Abstract: White Matter Disease is increasingly being recognized as an important cause of cognitive decline and dementia. Various investigations have linked chronic diet-related conditions to the development of white matter lesions, which appear as white matter hyperintensities on T2-weighted magnetic resonance imaging (MRI) scans of the brain. Thus, it can be postulated that the metabolic, inflammatory, and microvascular changes accompanying a western diet, hyperlipidemia, hypertension, and diabetes mellitus type II (DMII) are potential mediators in the development and progression of white matter disease, which in turn contributes to the development and progression of cognitive decline. This review will examine evidence for potential metabolic, inflammatory, and microvascular determinants of white matter disease and cognitive decline. Specifically, we will focus on the effects of altered insulin signaling in diabetes, obesity-induced oxidative stress, neuroinflammation, arterial stiffness due to hypertension, ischemia secondary to cerebral small vessel disease, and blood brain barrier disturbances.

Keywords: Alzheimer’s disease, cognitive impairment, dementia, inflammation, neurodegenerative disorders, western diet, white matter disease, vascular biology

Introduction

Alzheimer’s disease is the most common cause of dementia and has been cited as the sixth-leading cause of death in the United States [1]. According to a recent study using the latest data from the 2010 U.S. Census and the Chicago Heath and Aging Project, it is estimated that 5.1 million Americans age 65 and older have Alzheimer’s disease [2]. Given that age is a risk factor for Alzheimer’s disease and other dementias, the number of new and existing cases is predicted to increase as the segment of U.S. elderly (age 65 or over) population increase substantially, especially in the coming years as the baby boom generation ages. However, it is unclear whether the increase in cases of Alzheimer’s disease and other dementias are solely due to increasing age or whether chronic diet-related conditions, such as obesity and diabetes, are also responsible.

The western diet, characterized by high-fat, high-sugar, and excess salt composition, has been linked to major chronic diseases, such as atherosclerosis, hypertension, hyperlipidemia, obesity, and diabetes mellitus type II (DMII). Consumption of the western diet has also been associated with an increased risk for depression and cognitive decline [3-5]. This is consistent with previous studies that have demonstrated that cognitive impairment and decline is more prevalent among patients with metabolic syndrome and that metabolic syndrome is associated with greater risk of dementia later in life [6]. Lower intake of nutrient-dense foods and higher intake of processed “fast foods” have also been found to be independently associated with smaller left hippocampal volume [5], further supporting the concept that consumption of the western diet contributes to the development and progression of cognitive dysfunction.

In the past, most research performed on neurodegenerative diseases primarily focused on deleterious changes in the gray matter of the brain. More recently, diffuse white matter dis-
Western diet, white matter disease, and cognitive decline

Metabolic determinants

Diabetes

Among patients with DMII, cognitive function was found to have an inverse relationship with hemoglobin A1C levels [18]. This corresponds with another study which showed that diabetic patients had greater white matter hyperintensity volume and brain tissue loss compared to non-diabetic patients. Furthermore, it was shown that long-term weight loss interventions were associated with lower white matter hyperintensity volume, suggesting that treating diabetes itself may be the key to preventing neurodegeneration and thus, cognitive decline in diabetic patients [15]. While the mechanism underlying how DMII contributes to the development and progression of cognitive decline remains unclear, the current literature has proposed various theories that may explain why patients with DMII are at higher risk of neurodegenerative diseases. Recent investigations suggest that altered insulin signaling may be a contributory factor in cognitive decline. It is well-known that insulin receptors are highly expressed in cognition-related regions of the brain, as well as the blood brain barrier [19]. One study revealed that reduced brain insulin signaling in mouse models of diabetes increased tau beta phosphorylation and amyloid beta peptide levels, both of which are hallmark characteristics of Alzheimer’s disease [20-22]. Some researchers suggest that insulin resistance at the blood brain barrier reduces the amount of glucose that can reach the brain, resulting in neuronal injury [23]. While others proposed that the diabetic state may lead to a hyperglycemic condition in the brain that would result in the formation of glycated end products, which in turn can induce neuroinflammation [23]. Thus, both hyperglycemic and hypoglycemic conditions in the brain can lead to cognitive dysfunction. On the whole, there is limited information elucidating the mechanistic interactions between diabetes and cognitive decline, and more specifically how the metabolic changes that come with DMII affects white matter tissue in the brain. Although there is strong data showing that diabetic patients have higher prevalence of white matter hyperintensities and cognitive decline, more research is needed to decode how insulin resistance and/or hyperglycemia directly leads to white matter disease and cognitive decline.
Obesity and metabolic syndrome

Central obesity is an independent risk factor of dementia. Larger sagittal abdominal diameter was shown to be associated with an increased risk of developing dementia [24]. This is consistent with a number of studies that have shown that patients with higher body mass index (BMI) were more likely to develop Alzheimer’s disease later in life [25]. Obesity also has been shown to be independently associated with brain imaging changes before the clinical manifestation of cardiovascular or cerebrovascular disease [14]. Obese individuals were more likely to have decreased total cerebral volume and reduced white matter integrity compared to non-obese individuals [14, 16]. Likewise, studies indicate that patients with metabolic syndrome have higher brain fatty acid uptake and greater accumulation of fatty acids in the brain in comparison to healthy subjects, with white matter having the highest mean percentage increment [26]. In mouse model studies, it was shown that diet-induced obesity produced higher levels of reactive oxygen species in the brain [27]. Hence, oxidative stress may be responsible for cognitive dysfunction following obesity. This relationship between obesity and cognitive decline suggests that treating obesity itself may lead to better cognitive health. Although there is not sufficient evidence to support the use of bariatric surgery for the prevention and treatment of dementia in obese patients, there has been clinical research showing improved memory function two years following bariatric surgery [28]. Overall, current literature shows that obesity has a deleterious effect on the brain but further investigation is needed to better understand the relationship between obesity, white matter disease, and cognitive dysfunction.

Inflammatory determinants

RAGE signaling, COX-2 expression, and platelet activation

Mounting evidence points to neuroinflammation as a key contributor of cognitive decline [29]. Various studies have linked high serum levels of inflammatory markers, such as C-reactive protein, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6), with cognitive dysfunction [30, 31]. One hypothesized mechanism explaining this relationship between neuroinflammation and cognitive decline involves activation of receptors of advanced glycation end-products (RAGE), which are present on microglia and neurons in the brain, including the hippocampus, entorhinal cortex, and superior frontal gyrus [32]. RAGE activation turns on nuclear factor kappa B (NF-κB), which is a transcription factor that controls several pro-inflammatory genes. Some have suggested that RAGE could be involved in the injury of the brain in Alzheimer’s disease through neuroinflammation triggered by activation of RAGE signaling [33]. This is consistent with a study that demonstrated that diabetic patients with mild cognitive impairment had significantly higher serum levels of advanced glycated end-products (AGEs), RAGE, and C-reactive protein compared to diabetic patients without mild cognitive impairment [34]. Furthermore, amyloid-beta peptides activate cyclooxygenase-2 (COX-2) expression in a dose-dependent manner and treatment with COX-2 inhibitors or ibuprofen was shown to reverse this effect, suggesting that non-steroidal anti-inflammatory drugs (NSAIDs) may be used to reduce the risk of Alzheimer’s disease [35]; however, other studies suggest that COX-2 inhibitors may hasten dementia [36]. Hence, it remains controversial whether NSAIDs can be used in the treat-
Western diet, white matter disease, and cognitive decline

Recent literature has shown that inflammation-related cytokines and growth factors have been inversely associated with integrity of myelin sheath in individuals with bipolar disorder [37]. Activation of platelet function also has been associated with white matter lesions accompanied by cognitive decline [38]. Thus, it can be postulated that neuroinflammation induces white matter damage, which further promotes cognitive dysfunction.

Microvascular determinants

Hypertension: arterial stiffness and ischemia

Even before the manifestation of cardiovascular or cerebrovascular disease, hypertension has been linked to whole-brain volumetric reductions and variable pattern of increased white matter hyperintensities [14]. Although the exact mechanism behind how hypertension exacerbates cognitive dysfunction is still unclear, various studies have suggested that arterial stiffness is responsible for cognitive decline in patients with hypertension [39-41]. Current literature also has shown strong direct correlations between arterial stiffness and white matter hyperintensities [42], reinforcing the link between hypertension and cognitive decline. An additional explanation of how hypertension contributes to cognitive decline is ischemia caused by cerebral small vessel disease. Studies have shown that elevated blood pressure is a risk factor of cerebral small vessel disease [43] and that severity of cerebral small vessel disease is strongly correlated with severity of cognitive impairment [44]. Additionally, perfusion MRI studies have shown that white matter hyperintensities regions are characterized by decreased blood flow [45]. Thus, it makes sense that blunting or reversing the decrease in cerebral blood flow through the use of antihypertensive treatments would be associated with improved cognitive function [46].

Blood brain barrier dysfunction

Recently, it has been observed in multiple studies that rats fed with high energy diets, specifically diets rich in saturated fats and cholesterol, have increased blood brain barrier permeability along with cognitive dysfunction [47-49]. In conjunction with these studies, another investigation demonstrated that anti-inflammatory and lipid-lowering agents could reverse the high fat-induced blood brain barrier damage in rats [47]. Since blood brain barrier injury has been recognized as another contributory factor to the development and progression of cognitive impairment, it would be expected that reversal of blood brain barrier damage will be accompanied with improvement in cognitive function. However, the current level of evidence from several randomized controlled trials have been inconclusive in showing whether lipid-lowering medications, such as statins, can be used for the prevention or treatment of dementia [50].

Conclusions and clinical implications

Consumption of the western diet contributes to the development of major chronic diseases, such as diabetes, obesity, hyperlipidemia, and hypertension. In turn, these chronic conditions lead to metabolic, inflammatory, and microvascular changes that affect many parts of our body, including the brain. The western diet is also suspected to directly contribute to cognitive impairment as a result of increases in blood lipids, sugars, and sodium. Our review shows that metabolic, inflammatory, and microvascular changes accompanying chronic diet-related diseases play a significant role in promoting cognitive decline. Abundance evidence shows that there is a strong correlation between these factors and white matter lesions in the brain, allowing us to reasonably speculate that these factors do so by inducing damage to the white matter (Figure 1). Consequently, treating these chronic conditions, such as obesity, diabetes, and hypertension, may be the key to preventing the development and progression of white matter disease and cognitive decline. However, sufficient evidence to recommend anti-inflammatory or lipid-lowering drugs for the prevention and treatment of dementia is not currently available. Further investigation is needed to elucidate the exact mechanistic interactions between these metabolic, inflammatory, and microvascular determinates and white matter disease. A mechanistic understanding of white matter disease is essential to improving our current approach to preventing and treating neurodegenerative diseases, as well as identifying potential targets for further drug development.
Acknowledgements

This work was supported by the UC Davis Medical Student Research Fellowship Fund, the Richard A. and Nora Eccles Harrison Endowed Chair in Diabetes Research Fund, and the National Institutes of Health through the following grants: the National Center for Advancing Translational Sciences UL1 TR-001860, National Institute on Aging R01 AG039094, and National Institute of Diabetes and Digestive and Kidney Diseases U24 DK092993-05S1 (to J.C. Rutledge) and U24 DK092993 (to K, Lloyd). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosure of conflict of interest

None.

Address correspondence to: Maggie Wang and John C Rutledge, 451 East Health Science Drive, Genome and Biomedical Sciences Facility, Suite 5404, Davis, CA 95616, USA. Tel: 626-560-9596; E-mail: mawang@ucdavis.edu (MW); jcrutledge@ucdavis.edu (JCR)

References

Western diet, white matter disease, and cognitive decline


Western diet, white matter disease, and cognitive decline


